TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsPharos recalls, destroys food supplement after BPOM pork finding
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Heavy equipment destroys the Viostin DS food supplement on Feb. 8 after the Food and Drug Monitoring Agency found the product contained pork derivatives. (Courtesy of/PT Pharos Indonesia)
P
T Pharos Indonesia, a producer of the Viostin DS food supplement, has recalled and destroyed the product after the Food and Drug Monitoring Agency (BPOM) found it contained pork derivatives.
Pharos Indonesia spokesperson Ida Nurtika said the recall process for the 20 tons of product began in November 2017.
“The destroying [of the product] reflects our transparency and our responsibility to society,” Ida said in a statement received by The Jakarta Post on Friday.
Previously, beef, instead of pork, was used a raw material in Viostin DS, the company said in a press statement. However, it had recalled the product after the BPOM finding.
In addition to the Viostin DS supplement, the Enzyplex supplement had also been recalled over concerns of pork derivatives. The BPOM instructed its representatives throughout the country to closely monitor the process to ensure the products were completely recalled from the market.
The BPOM laboratory tested samples from Viostin DS batch BN C6K994H, produced by PT Pharos Indonesia, and Enzyplex batch 16185101, produced by PT Medifarma Laboratories.
Pharos said that although the BPOM only required that the company recall certain batches of the product, it preferred to recall all Viostin DS from the market. (bbn)
